Full history for every metric is available with a Kvantra account

Stock profile
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
96.0
History
P/E NTM
24.5
Market cap
9.57B
Currency USD
KvantraRankAbout58
IValue58
IIQuality42
IIIMomentum82
Current price
63.34 USD-2.37%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m073234329616898994
Operating profit$m123193
Net profit$m-279-348-2241323447106175
EPS reported$2.770.66
Operating cashflow per share$-0.170.61
Capex per share$0.000.00
FCF per share$-0.170.61
Free cash flow$m-25.085.6
Net debt$m119250
Book value equity$m648572
Book value per share$4.013.67
Number of sharesm161.41155.93
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx10.7695.97
P/B LTMx6.6416.73
P/S LTMx6.9810.66
P/FCF LTMx-172.18111.89
EV/EBITDA LTMx33.3751.34
EV/Sales LTMx7.2810.94
Earnings Yield LTM%9.29%1.04%
FCF Yield%-0.58%0.89%
Quality
ROE%69.01%17.62%
ROIC%13.54%10.26%
Operating margin%20.01%21.48%
Gross margin%83.66%82.74%
FCF/Sales%-4.05%9.53%
Growth and momentum
EPS Growth YoY%+1746.7%-76.26%
Sales Growth YoY%+87.32%+68.78%
Net Income Growth YoY%+1812.4%-76.30%
FCF Growth%--
Operating Profit Growth%+194.13%+87.65%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx-0.100.11
Net Debt/EBITDAx1.351.70
EBIT/Net interestx4.614.14
Net debt/market cap%2.76%2.61%
Net debt/Equityx0.180.44
Gross debt/equityx0.401.32

ETFs that hold TG Therapeutics

FundTickerPosition#Weight
iShares Core S&P Small-Cap ETFIJR50.52%
iShares Russell 2000 ETFIWM60.32%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM50.53%
iShares Russell 2000 Growth ETFIWO50.63%
State Street SPDR S&P Biotech ETFXBI61.77%
iShares S&P Small-Cap 600 Growth ETFIJT31.11%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG31.11%
State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)R2US.L80.31%
First Trust NYSE Arca Biotechnology Index FundFBT63.80%
iShares S&P SmallCap 600 UCITS ETFIDP6.L60.52%

Funds with TG Therapeutics among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price63.34 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

TG Therapeutics, Inc. (TGTX)

TGTX · NASDAQ · Healthcare
63.34 USD-2.37%
Sign up to track this stock
Benchmarks
KvantraRank58
Market cap9.57B
P/E NTM24.5
P/E TTM96.0
KvantraRank?58 / 100
Value
58
Quality
42
Momentum
82
Financialsin USD
20242025TTM2026E
ETFs that hold TG Therapeutics
FundTickerPosition#Weight
iShares Core S&P Small-Cap ETFIJR50.52%
iShares Russell 2000 ETFIWM60.32%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM50.53%
iShares Russell 2000 Growth ETFIWO50.63%
State Street SPDR S&P Biotech ETFXBI61.77%
iShares S&P Small-Cap 600 Growth ETFIJT31.11%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG31.11%
State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)R2US.L80.31%
First Trust NYSE Arca Biotechnology Index FundFBT63.80%
iShares S&P SmallCap 600 UCITS ETFIDP6.L60.52%

Funds with TG Therapeutics among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current63.34 USD
Upside
Price consensus
Last year average price target
Current price63.34 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free